Issue Date: March 17, 2008
Suven Signs Second Deal With Lilly
Suven Life Sciences and Eli Lilly & Co. have signed a second drug discovery collaboration in the area of small molecules that treat central nervous system disorders. Suven says it will receive research funding and possible milestone payments ranging from $19 million to $23 million per drug candidate. The two companies signed a similar deal in August 2006.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society